SEARCH:   Advanced

Blood, 15 August 2006, Vol. 108, No. 4, pp. 1377-1380. Prepublished online as a Blood First Edition Paper on May 4, 2006; DOI 10.1182/blood-2005-11-009605. This Article Full Text Full Text (PDF) Supplemental Table, Figures, and Data All Versions of this Article: blood-2005-11-009605v1 108/4/1377    most recent Alert me when this article is cited Alert me if a correction is posted Citation Map Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Download to citation manager Rights and Permissions Citing Articles Citing Articles via HighWire Citing Articles via CrossRef Citing Articles via Google Scholar Google Scholar Articles by Kralovics, R. Articles by Skoda, R. C. Search for Related Content PubMed PubMed Citation Articles by Kralovics, R. Articles by Skoda, R. C. Related Collections Neoplasia Oncogenes and Tumor Suppressors Signal Transduction Brief Reports Social Bookmarking                   What's this?  Previous Article  |  Table of Contents  |  Next Article  NEOPLASIA Brief report Acquisition of the V617F mutation of JAK2 is a late genetic event in a subset of patients with myeloproliferative disorders Robert Kralovics, Soon-Siong Teo, Sai Li, Alexandre Theocharides, Andreas S. Buser, Andre Tichelli, and Radek C. Skoda From the Department of Research, Experimental Hematology, the Division of Clinical Hematology, and the Division of Diagnostic Hematology, Basel University Hospital, Switzerland. An acquired gain-of-function mutation in the Janus kinase 2 (JAK2-V617F) is frequently found in patients with myeloproliferative disorders (MPDs). To test the hypothesis that JAK2-V617F is the disease-initiating mutation, we examined whether all cells of clonal origin carry the JAK2-V617F mutation. Using allele-specific polymerase chain reaction (PCR) assays for the JAK2 mutation and for the X-chromosomal clonality markers IDS and MPP1, we found that the percentage of granulocytes and platelets with JAK2-V617F was often markedly lower than the percentage of clonal granulocytes determined by IDS or MPP1 clonality assays in female patients. Using deletions of chromosome 20q (del20q) as an autosomal, X-chromosome–independent clonality marker, we found a similar discrepancy between the percentage of cells carrying JAK2-V617F and del20q. Our results suggest that in a proportion of patients with MPDs, JAK2-V617F occurs on the background of clonal hematopoiesis caused by a somatic mutation in an as-yet-unknown gene. CiteULike    Connotea    Del.icio.us    Digg    Reddit    Technorati    What's this? This article has been cited by other articles: J. L. Spivak and R. T. Silver The revised World Health Organization diagnostic criteria for polycythemia vera, essential thrombocytosis, and primary myelofibrosis: an alternative proposal Blood, July 15, 2008; 112(2): 231 - 239. [Full Text] [PDF] A. M. Vannucchi and P. Guglielmelli Molecular pathophysiology of Philadelphia-negative myeloproliferative disorders: beyond JAK2 and MPL mutations Haematologica, July 1, 2008; 93(7): 972 - 976. [Full Text] [PDF] R. Tiedt, H. Hao-Shen, M. A. Sobas, R. Looser, S. Dirnhofer, J. Schwaller, and R. C. Skoda Ratio of mutant JAK2-V617F to wild-type Jak2 determines the MPD phenotypes in transgenic mice Blood, April 15, 2008; 111(8): 3931 - 3940. [Abstract] [Full Text] [PDF] S. Li, R. Kralovics, G. De Libero, A. Theocharides, H. Gisslinger, and R. C. Skoda Clonal heterogeneity in polycythemia vera patients with JAK2 exon12 and JAK2-V617F mutations Blood, April 1, 2008; 111(7): 3863 - 3866. [Abstract] [Full Text] [PDF] A. H. Schmitt-Graeff, S.-S. Teo, M. Olschewski, F. Schaub, S. Haxelmans, A. Kirn, P. Reinecke, U. Germing, and R. C. Skoda JAK2V617F mutation status identifies subtypes of refractory anemia with ringed sideroblasts associated with marked thrombocytosis Haematologica, January 1, 2008; 93(1): 34 - 40. [Abstract] [Full Text] [PDF] A. Pardanani, T. L. Lasho, C. Finke, R. A. Mesa, W. J. Hogan, R. P. Ketterling, D. G. Gilliland, and A. Tefferi Extending Jak2V617F and MplW515 Mutation Analysis to Single Hematopoietic Colonies and B and T Lymphocytes Stem Cells, September 1, 2007; 25(9): 2358 - 2362. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green Methuselah conundrum: MPDs in the elderly Blood, September 1, 2007; 110(5): 1409 - 1409. [Full Text] [PDF] G. L. Chen and J. T. Prchal X-linked clonality testing: interpretation and limitations Blood, September 1, 2007; 110(5): 1411 - 1419. [Abstract] [Full Text] [PDF] J. T. Prchal The amount of JAK2 617V>F matters Blood, August 1, 2007; 110(3): 796 - 797. [Full Text] [PDF] S. Dupont, A. Masse, C. James, I. Teyssandier, Y. Lecluse, F. Larbret, V. Ugo, P. Saulnier, S. Koscielny, J. P. Le Couedic, et al. The JAK2 617V>F mutation triggers erythropoietin hypersensitivity and terminal erythroid amplification in primary cells from patients with polycythemia vera Blood, August 1, 2007; 110(3): 1013 - 1021. [Abstract] [Full Text] [PDF] A. Theocharides, M. Boissinot, F. Girodon, R. Garand, S.-S. Teo, E. Lippert, P. Talmant, A. Tichelli, S. Hermouet, and R. C. Skoda Leukemic blasts in transformed JAK2-V617F-positive myeloproliferative disorders are frequently negative for the JAK2-V617F mutation. Blood, July 1, 2007; 110(1): 375 - 379. [Abstract] [Full Text] [PDF] K. Hussein, O. Bock, A. Seegers, M. Flasshove, F. Henneke, G. Buesche, and H. H. Kreipe Myelofibrosis evolving during imatinib treatment of a chronic myeloproliferative disease with coexisting BCR-ABL translocation and JAK2V617F mutation Blood, May 1, 2007; 109(9): 4106 - 4107. [Full Text] [PDF] L. M. Scott, W. Tong, R. L. Levine, M. A. Scott, P. A. Beer, M. R. Stratton, P. A. Futreal, W. N. Erber, M. F. McMullin, C. N. Harrison, et al. JAK2 Exon 12 Mutations in Polycythemia Vera and Idiopathic Erythrocytosis N. Engl. J. Med., February 1, 2007; 356(5): 459 - 468. [Abstract] [Full Text] [PDF] R. E. Gale, A. J.R. Allen, M. J. Nash, and D. C. Linch Long-term serial analysis of X-chromosome inactivation patterns and JAK2 V617F mutant levels in patients with essential thrombocythemia show that minor mutant-positive clones can remain stable for many years Blood, February 1, 2007; 109(3): 1241 - 1243. [Abstract] [Full Text] [PDF] R. Skoda The Genetic Basis of Myeloproliferative Disorders Hematology, January 1, 2007; 2007(1): 1 - 10. [Abstract] [Full Text] [PDF] P. J. Campbell and A. R. Green The Myeloproliferative Disorders N. Engl. J. Med., December 7, 2006; 355(23): 2452 - 2466. [Full Text] [PDF] A. D. Pardanani, R. L. Levine, T. Lasho, Y. Pikman, R. A. Mesa, M. Wadleigh, D. P. Steensma, M. A. Elliott, A. P. Wolanskyj, W. J. Hogan, et al. MPL515 mutations in myeloproliferative and other myeloid disorders: a study of 1182 patients Blood, November 15, 2006; 108(10): 3472 - 3476. [Abstract] [Full Text] [PDF]

	Copyright © 2006 by American Society of Hematology         Online ISSN: 1528-0020